| |
Revolutionize your clinical trial! IQVIA experts discuss how the synergy between wearables and eCOA will enhance data collection, patient engagement, regulatory compliance and streamline trial processes. Watch this webinar replay now.
|
|
Today’s Big NewsJul 15, 2025 |
| By Angus Liu Sino Biopharm said it will pay up to $951 million to acquire LaNova Medicines, which has ongoing oncology partnerships with Merck & Co. and AstraZeneca. |
|
|
|
By James Waldron Hengrui Pharma has tied its injectable GLP-1/GIP receptor dual agonist to a mean weight loss of almost 18% at 48 weeks, leading the biotech to push for approval in China “as soon as possible.” |
By James Waldron Days after JCR Pharmaceuticals signed a deal with AstraZeneca’s rare disease unit, the Japanese biopharma has secured a $555 million biobucks pact with Alzheimer’s-focused Acumen Pharmaceuticals. |
Sponsored by Evernorth Specialty Services Choosing the right specialty pharmacy partner is critical. Especially when you’re treating rare, chronic and complex conditions. You need a partner who delivers more than just logistics management, therapy fulfillment and generalized patient care. |
|
Overcome biotherapeutic protein expression challenges with advanced vector technology for a range of multi-gene and difficult to express proteins. Watch the presentation to learn more.
|
|
By Gabrielle Masson Sellas Life Sciences’ investigational CDK9 inhibitor has scored in a midstage acute myeloid leukemia (AML) study, demonstrating an overall response rate (ORR) more than double the 20% goal. |
By Gabrielle Masson International companies are increasingly inking licensing deals with Chinese biotechs as concerns regarding drug pricing and patent expirations continue to rise. |
By Darren Incorvaia Even with the HIV prevention waters now dominated by Gilead Science’s Yeztugo (lenacapavir), Merck & Co. is not afraid to swim deeper in. The New Jersey pharma is teaming up with the Gates Foundation to launch a pair of phase 3 trials of its once-monthly, oral pre-exposure prophylaxis (PrEP) prospect. |
By Andrea Park As Miami-based Veru continues development of its enobosarm to prevent muscle wasting in patients being treated for obesity, among other conditions, the biopharma has conducted a survey showing that the side effect looms large in the minds of GLP-1 users. |
By Fraiser Kansteiner With transatlantic expansions nearing completion and a new acquisition in the books, PCI Pharma Services has secured a confidence vote—and capital to go with it—from a slate of private equity heavy hitters, including new backer Bain Capital. |
By Noah Tong A new lawsuit puts the use of AI by third-party vendors in denying medical diagnoses under the spotlight. |
By Dave Muoio Michael Kirk Moore, a certified plastic surgeon in Utah, and others were indicted by a federal grand jury in 2023 and faced up to 35 years in prison. His case had become a focal point for conservatives critical of the COVID-19 pandemic response under President Joe Biden and others more broadly skeptical of vaccination. |
Fierce podcastsDon’t miss an episode |
| | Biopharma layoffs have held steady through mid-2025, and in this episode of "The Top Line," we dig into the numbers, closures and policy changes shaping the trend. |
|
|---|
|
|
| WhitepaperThis white paper outlines how we apply industry-backed practices and proprietary technologies to proactively safeguard sterility and performance. Sponsored by: Lonza |
| WhitepaperPresented by Blue Matter, strategic consultants in the life sciences Sponsored by Blue Matter Consulting |
| Executive SummaryBiotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster. Sponsored by: IQVIA Laboratories |
| |
|
